Maven TMF PO, SungSu Cha (left) and Maven X Development Lead, HyeYeon Shin (right)
Clinical trials are a race against time. Developing new drugs can take over 10 years and cost billions of won.
JNPMEDI, a clinical data management platform company has pledged to significantly reduce the time and costs involved in clinical trials through digital transformation of clinical trials.
To this end, last month, JNPMEDI launched the โMaven TMFโ solution, which digitizes traditional paper-based clinical trial management documents (TMF) and is designed to efficiently store, access, and manage documents and data.
The Project Owner (PO) of Maven TMF, SungSu Cha, explained, โMaven TMF uses blockchain technology to ensure data integrity, a crucial element for the successful execution of clinical trials.โ
The standout feature of โMaven TMFโ is its reliance on cloud based technology. In contrast to earlier solutions that could only be accessed via limited servers, โMaven TMFโ is a web-based service, allowing unrestricted access to documents from any location, at any time.
Another advantage is that it integrates smoothly with JNPMEDIโs clinical trial cloud ecosystem, enabling seamless interaction with various tools, including clinical data management solutions. Internally, JNPMEDI uses its own clinical trial solutions, such as โMaven Xโ, which is constantly being improved to track the real-time progress of clinical trials.
HyeYeon Shin, the Development Lead of โMaven Xโ stated, โMaven X ensures consistent quality across clinical trials.โ and further added that Contract Research Organizations (CROs) must follow standard operating procedures (SOPs) and โMaven Xโ helps maintain adherence to these procedures and standards.
She continued, โMaven X is designed to cover the full spectrum of clinical trials, from contract to project completion. It offers a collaborative solution that not only facilitates the trials but also provides metrics to measure their success. When integrated with โMaven TMFโ, it creates the synergy by providing a unified view of previously fragmented information.โ
JNPMEDI also highlighted its focus on conducting efficient and successful clinical trials by incorporating client feedback and requirements.
Before joining JNPMEDI, Cha, who was responsible for clinical trial research, monitoring, and management at pharmaceutical companies such as AstraZeneca Korea, is actively proposing ideas at JNPMEDI to address the inconveniences he experienced as an "end user" during that time.
He shared, โRecently, we received feedback requesting a system to clearly assign responsible experts during the review process of clinical trial documents. We implemented improvements based on this and since JNPMEDI is an IT company with a well-established development team, we are capable of responding quickly.โ
JNPMEDI also expressed confidence in its strong security technology. Through obtaining the Amazon Web Services (AWS) Partner Software Path, JNPMEDI provides stable services to its clients. The company has also acquired international information security standards, such as ISO 27001.
JNPMEDI is determined to present solutions that meet the needs of various stakeholders, based on its excellent security capabilities.
Additionally, the company revealed plans to enhance operational efficiency by leveraging artificial intelligence (AI). In addition to the next-generation medical coder โMaven Coder Expressโ, developed using AWSโs generative AI technology, JNPMEDI plans to use AI in pharmacovigilance (PV) to detect potential drug side effects and quickly report and evaluate them.
Furthermore, the company is actively recruiting experts with experience in the CRO industry to grow as a trusted medical data platform provider.
PO Cha emphasized, "We are continuously recruiting individuals with extensive knowledge and experience in clinical trials, presenting solutions that ensure high accuracy and quickly address customer needs." He further stated, "Based on our management philosophy of 'innovation,' we will continue to freely exchange ideas with other departments and present excellent solutions, as we have done so far."
Maven TMF PO, SungSu Cha (left) and Maven X Development Lead HyeYeon Shin,ย
are being interviewed atย JNPMEDI's headquarter in Songdo, Incheon
๐ Original Article : https://n.news.naver.com/mnews/article/029/0002938139?sid=105ย
Maven TMF PO, SungSu Cha (left) and Maven X Development Lead, HyeYeon Shin (right)
Clinical trials are a race against time. Developing new drugs can take over 10 years and cost billions of won.
JNPMEDI, a clinical data management platform company has pledged to significantly reduce the time and costs involved in clinical trials through digital transformation of clinical trials.
To this end, last month, JNPMEDI launched the โMaven TMFโ solution, which digitizes traditional paper-based clinical trial management documents (TMF) and is designed to efficiently store, access, and manage documents and data.
The Project Owner (PO) of Maven TMF, SungSu Cha, explained, โMaven TMF uses blockchain technology to ensure data integrity, a crucial element for the successful execution of clinical trials.โ
The standout feature of โMaven TMFโ is its reliance on cloud based technology. In contrast to earlier solutions that could only be accessed via limited servers, โMaven TMFโ is a web-based service, allowing unrestricted access to documents from any location, at any time.
Another advantage is that it integrates smoothly with JNPMEDIโs clinical trial cloud ecosystem, enabling seamless interaction with various tools, including clinical data management solutions. Internally, JNPMEDI uses its own clinical trial solutions, such as โMaven Xโ, which is constantly being improved to track the real-time progress of clinical trials.
HyeYeon Shin, the Development Lead of โMaven Xโ stated, โMaven X ensures consistent quality across clinical trials.โ and further added that Contract Research Organizations (CROs) must follow standard operating procedures (SOPs) and โMaven Xโ helps maintain adherence to these procedures and standards.
She continued, โMaven X is designed to cover the full spectrum of clinical trials, from contract to project completion. It offers a collaborative solution that not only facilitates the trials but also provides metrics to measure their success. When integrated with โMaven TMFโ, it creates the synergy by providing a unified view of previously fragmented information.โ
JNPMEDI also highlighted its focus on conducting efficient and successful clinical trials by incorporating client feedback and requirements.
Before joining JNPMEDI, Cha, who was responsible for clinical trial research, monitoring, and management at pharmaceutical companies such as AstraZeneca Korea, is actively proposing ideas at JNPMEDI to address the inconveniences he experienced as an "end user" during that time.
He shared, โRecently, we received feedback requesting a system to clearly assign responsible experts during the review process of clinical trial documents. We implemented improvements based on this and since JNPMEDI is an IT company with a well-established development team, we are capable of responding quickly.โ
JNPMEDI also expressed confidence in its strong security technology. Through obtaining the Amazon Web Services (AWS) Partner Software Path, JNPMEDI provides stable services to its clients. The company has also acquired international information security standards, such as ISO 27001.
JNPMEDI is determined to present solutions that meet the needs of various stakeholders, based on its excellent security capabilities.
Additionally, the company revealed plans to enhance operational efficiency by leveraging artificial intelligence (AI). In addition to the next-generation medical coder โMaven Coder Expressโ, developed using AWSโs generative AI technology, JNPMEDI plans to use AI in pharmacovigilance (PV) to detect potential drug side effects and quickly report and evaluate them.
Furthermore, the company is actively recruiting experts with experience in the CRO industry to grow as a trusted medical data platform provider.
PO Cha emphasized, "We are continuously recruiting individuals with extensive knowledge and experience in clinical trials, presenting solutions that ensure high accuracy and quickly address customer needs." He further stated, "Based on our management philosophy of 'innovation,' we will continue to freely exchange ideas with other departments and present excellent solutions, as we have done so far."
Maven TMF PO, SungSu Cha (left) and Maven X Development Lead HyeYeon Shin,ย
are being interviewed atย JNPMEDI's headquarter in Songdo, Incheon
๐ Original Article : https://n.news.naver.com/mnews/article/029/0002938139?sid=105ย